US Markets
AZN

Oxford COVID-19 vaccine trials produce robust immune response in elderly - FT

Credit: REUTERS/DADO RUVIC

The COVID-19 vaccine being developed by the University of Oxford and AstraZeneca Plc produces a robust immune response in elderly people, the group at highest risk, the Financial Times said on Monday, citing early results.

Oxford vaccine produces robust immune response in elderly

Early results cited by FT

Details of the findings shortly to be published - FT

Adds details

Oct 26 (Reuters) - The COVID-19 vaccine being developed by the University of Oxford and AstraZeneca Plc AZN.L produces a robust immune response in elderly people, the group at highest risk, the Financial Times said on Monday, citing early results.

The vaccine triggers protective antibodies and T-cells in older age groups, the FTsaid, citing two people familiar with the finding, encouraging researchers as they seek evidence that it will spare those in later life from serious illness or death from the virus.

Details of the finding are expected to be published shortly in a clinical journal, the FT said, without naming the publication.

The findings echo data released in July which showed the vaccine generated "robust immune responses" in a group of healthy adults aged between 18 and 55, the newspaper reported, citing people aware of the results from so-called immunogenicity blood tests.

But the FT cautioned that positive immunogenicity tests do not guarantee that the vaccine will ultimately prove safe and effective in older people.

AstraZeneca, which is developing the vaccine with Oxford University researchers, is seen as a frontrunner in the race to produce a vaccine to protect against COVID-19.

Oxford and AstraZeneca did not immediately respond to Reuters' request for comments.

One of the world's leading coronavirus vaccine candidates, called AZD1222 or ChAdOx1 nCoV-19, was developed by Oxford University scientists and licensed to AstraZeneca in April, which took on the task of scaling trials and production.

AstraZeneca resumed the U.S. trial of the experimental vaccine after approval by U.S. regulators, the company said on Friday.

It is a viral vector vaccine that uses a weakened version of a chimpanzee common cold virus that encodes instructions for making proteins from the novel coronavirus to build immunity against COVID-19.

(Reporting by Bhargav Acharya in Bengaluru and Guy Faulconbridge in London; Editing by Simon Cameron-Moore and Tomasz Janowski)

((Bhargav.Acharya@thomsonreuters.com;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

AZN

Latest Markets Videos

    Reuters

    Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

    Learn More